Jennifer L. Fox

Ms. Fox focuses her practice on counseling pharmaceutical and biotechnology companies in patent and related transactional matters. As both a research scientist and patent attorney, she has over 15 years of experience in the pharmaceutical and biotechnology industries.

Prior to joining Brinks, Hofer, Gilson and Lione, Ms. Fox was the head of the Life Sciences and Biotechnology practice group at Coats + Bennett, PLLC, a boutique intellectual property firm just outside of Research Triangle Park, NC.

Before entering private practice, Ms. Fox worked as an in-house attorney for Novozymes North America, Inc. and previously worked as a pharmaceutical and biotechnology patent attorney for GlaxoSmithKline, Inc. (GSK).

In addition to her J.D., Ms.Fox holds a Master of Science in molecular biology and biochemistry. Following graduate school she worked as a research scientist at the National Institute of Health (NIH) and at Glaxo Wellcome, Inc. She has been published in numerous peer reviewed journals including Proceedings of the National Academy of Sciences, Biochemistry and Molecular Endocrinology.

• NC Lawyers Weekly Emerging Legal Leaders, 2010

• “Prometheus, Myriad, and the Future of Personalized Medicine,” North Carolina Bar Association Intellectual Property Section Publication, February 2011
• “Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662” Biochemistry 2002 May 28;41(21):6640-50
• “A Selective Peroxisome Proliferator-activated Receptor δ Agonist Promotes Reverse Cholesterol Transport" Proc Natl Acad Sci USA 2001 Apr 24;98(9);5306-5311
• “p53 Represses Androgen-Induced Transactivation of Prostate Specific Antigen by Disrupting hAR Amino-to-Carboxy Terminal Interaction" J Biol Chem 2001 Oct 19;276(42):38472-9
• “The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged During Evolution” Mol Endo 2000 Jan; 14(1):27-39

• "Patent Issues Unique to the Manufacturing of Biosimilars," Biosimilar Drug Development World Conference, London, March 2, 2012
• Instructor for PCT Administration CLE for paralegals, Spring, 2011
• "Elucidating mechanisms of action of orphan nuclear receptors using open-ended differential gene expression platforms," NIEHS Receptor Mechanisms Discussion Group, September, 2000
• "A novel class of PPARγ ligand that inhibits adipocyte differentiation," 81st Annual Endocrine Society Meeting, San Diego,Calif., June 1999.

• Council for Entrepreneurial Development
• Women in Bio
• Healthcare Businesswomen’s Association
• North Carolina Bar Association
• American Intellectual Property Law Association

• Brinks Hofer Gilson & Lione Adds Attorneys in Two Offices

• Drug Discovery News